Hepatocellular carcinoma in patients with chronic kidney disease

被引:18
作者
Lee, Chern-Horng [1 ,2 ]
Hsieh, Sen-Yung [1 ,3 ]
Lin, Ja-Liang [1 ,4 ]
Liu, Maw-Sen [1 ,2 ]
Yen, Tzung-Hai [1 ,4 ]
机构
[1] Chang Gung Univ, Coll Med, Tao Yuan 333, Taiwan
[2] Chang Gung Mem Hosp, Dept Gen Internal Med & Geriatr, Linkou 333, Taiwan
[3] Chang Gung Mem Hosp, Liver Res Unit, Tao Yuan 333, Taiwan
[4] Chang Gung Mem Hosp, Dept Nephrol, Taipei 105, Taiwan
关键词
Hepatocellular carcinoma; Hepatitis B virus; Hepatitis C virus; Chronic kidney disease; End-stage renal disease; STAGE RENAL-DISEASE; HEPATITIS-C VIRUS; TRANSITIONAL-CELL CARCINOMA; CANCER-SPECIFIC MORTALITY; B-VIRUS; MAINTENANCE HEMODIALYSIS; LIVER RESECTION; ASSOCIATION; DIALYSIS; FAILURE;
D O I
10.3748/wjg.v19.i16.2466
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate outcomes of hepatocellular carcinomas (HCCs) in patients with chronic kidney disease (CKD). METHODS: Four hundred and forty patients referred between 2000 and 2002 for management of HCCs were categorized according to their CKD stage, i.e., estimated glomerular filtration rate (eGFR) > 90 (stage 1), 60-90 (stage 2), 30-60 (stage 3), 15-30 (stage 4), and < 15 (stage 5) mL/min per 1.73 m(2), respectively. Demographic, clinical and laboratory data were collected and mortality rates and cause of mortality were analyzed. The mortality data were examined with Kaplan-meier method and the significance was tested using a log-rank test. An initial univariate Cox regression analysis was performed to compare the frequency of possible risk factors associated with mortality. To control for possible confounding factors, a multivariate Cox regression analysis (stepwise backward approach) was performed to analyze those factors that were significant in univariate models (P < 0.05) and met the assumptions of a proportional hazard model. RESULTS: Most HCC patients with CKD were elderly, with mean age of diagnosis of 60.6 +/- 11.9 years, and mostly male (74.8%). Hepatitis B, C and B and C co-infection virus were positive in 61.6%, 45.7% and 14.1% of the patients, respectively. It was found that patients with stages 4 and 5 CKD were not only older (P = 0.001), but also had higher hepatitis C virus carrier rate (P = 0.001), lower serum albumin level (P = 0.001), lower platelet count (P = 0.037), longer prothrombin time (P = 0.001) as well as higher proportions of advanced cirrhosis (P = 0.002) and HCCs (P = 0.001) than patients with stages 1 and 2 CKD. At the end of analysis, 162 (36.9%) patients had died. Kaplan-Meier analysis revealed that patients with stages 4 and 5 CKD suffered lower cumulative survival than stages 1 and 2 CKD (log-rank test, chi(2) = 11.764, P = 0.003). In a multivariate Cox-regression model, it was confirmed that CKD stage [odds ratio (OR) = 1.988, 95% CI: 1.012-3.906, P = 0.046)], liver cirrhosis stage (OR = 3.571, 95% CI: 1.590-8.000, P = 0.002) and serum albumin level (OR = 0.657, 95% CI: 0.491-0.878, P = 0.005) were significant predictors for mortality in this population. CONCLUSION: HCC patients with stages 4 and 5 CKD had inferior survival than stages 1 and 2 CKD. This warrants further studies. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:2466 / 2472
页数:7
相关论文
共 50 条
[31]   Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naive chronic hepatitis C patients in China [J].
Li, Xu ;
Xu, Hongqin ;
Gao, Yang ;
Pan, Meng ;
Wang, Le ;
Gao, Pujun .
MEDICINE, 2017, 96 (13)
[32]   HEPATITIS-C ANTIBODY IN PATIENTS WITH CHRONIC LIVER-DISEASE AND HEPATOCELLULAR-CARCINOMA [J].
COLOMBO, M ;
RUMI, MG ;
DONATO, MF ;
TOMMASINI, MA ;
DELNINNO, E ;
RONCHI, G ;
KUO, G ;
HOUGHTON, M .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (08) :1130-1133
[33]   Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study [J].
Ha, Nghi B. ;
Ha, Nghiem B. ;
Ahmed, Aijaz ;
Ayoub, Walid ;
Daugherty, Tami J. ;
Chang, Ellen T. ;
Lutchman, Glen A. ;
Garcia, Gabriel ;
Cooper, Allen D. ;
Keeffe, Emmet B. ;
Nguyen, Mindie H. .
CANCER CAUSES & CONTROL, 2012, 23 (03) :455-462
[34]   Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma [J].
Fouad, Shawky Abdelhamid ;
Mohamed, Nagwa Abdel Ghaffar ;
Fawzy, Mary Wadie ;
Moustafa, Doaa Ali .
HEPATITIS MONTHLY, 2015, 15 (09)
[35]   PREVALENCE OF HEPATITIS-C VIRUS-ANTIBODIES IN CHRONIC LIVER-DISEASE AND HEPATOCELLULAR-CARCINOMA PATIENTS IN INDIA [J].
RAMESH, R ;
MUNSHI, A ;
PANDA, SK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1992, 7 (04) :393-395
[36]   Valvular heart disease in patients with chronic kidney disease [J].
Ewen, S. ;
Mahfoud, F. ;
Lauder, L. ;
Scheller, B. ;
Boehm, M. .
INTERNIST, 2020, 61 (04) :368-374
[37]   Valvular Heart Disease in Patients with Chronic Kidney Disease [J].
Kipourou, Konstantina ;
O'Driscoll, Jamie M. ;
Sharman, Rajan .
EUROPEAN CARDIOLOGY REVIEW, 2022, 17
[38]   Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection [J].
Shimomura, Soji ;
Nishiguchi, Shuhei .
HEPATOLOGY RESEARCH, 2012, 42 (01) :22-32
[39]   Prophylactic vaccinations in chronic kidney disease: Current status [J].
Grzegorzewska, Alicja E. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (11) :2599-2605
[40]   The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients [J].
Huang, Jee-Fu ;
Yeh, Ming-Lun ;
Yu, Ming-Lung ;
Dai, Chia-Yen ;
Huang, Chung-Feng ;
Huang, Ching-I ;
Tsai, Pei-Chien ;
Lin, Pei-Chen ;
Chen, Yao-Li ;
Chang, Wen-Tsan ;
Hou, Nai-Jen ;
Lin, Zu-Yau ;
Chen, Shinn-Cherng ;
Chuang, Wan-Long .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) :1768-1774